Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
API-CAT: Reduced vs Full Dose Apixaban for Cancer-Associated VTE
NCT03692065Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2018
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of apixaban in venous thromboembolism (VTE), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Adjudicated composite endpoint of recurrent venous thromboembolism at 12 months. Started Oct 2018; status: completed.
02
Drugs
apixaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT03692065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03692065.